{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:08:14Z","timestamp":1779962894943,"version":"3.53.1"},"reference-count":28,"publisher":"Charles University in Prague, Karolinum Press","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":4241,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":4241,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","award":["259211\/110709"],"award-info":[{"award-number":["259211\/110709"]}],"id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["UNCE 204021"],"award-info":[{"award-number":["UNCE 204021"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["PRVOUK P24\/LF1\/3"],"award-info":[{"award-number":["PRVOUK P24\/LF1\/3"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fol. Biol."],"published-print":{"date-parts":[[2013]]},"abstract":"<jats:p>\n                    Mantle cell lymphoma (MCL) is an aggressive lymphoma subtype with dismal prognosis. New treatments are needed to improve outcome of relapsed\/refractory disease. Recently, several drugs targeting at least partially the process of angiogenesis have been successfully tested in the therapy of MCL. Molecular mechanisms that regulate MCL-induced angiogenesis and that might represent potential new druggable targets remain, however, incompletely understood. We established two mouse models of human MCL by subcutaneous xenotransplantation of JEKO-1 and HBL-2 cell lines into immunodeficient mice. Histological analyses of xenografts confirmed their neovascularization. The growth of xenografts was significantly suppressed by single-agent therapy with bevacizumab, monoclonal antibody targeting vascular endothelial growth factor (VEGF). Subsequently, we analysed expression of 94 angiogenesis-related genes in\n                    <jats:italic>ex vivo<\/jats:italic>\n                    isolated JEKO-1 and HBL-2 cells compared to\n                    <jats:italic>in vitro<\/jats:italic>\n                    growing cells using TaqMan low-density arrays. The most up-regulated genes in both JEKO-1 and HBL-2 xenografts were genes encoding platelet\/endothelial cell-adhesion molecule (\n                    <jats:italic>CD31\/PECAM1<\/jats:italic>\n                    ), VEGF receptor 1 (\n                    <jats:italic>FLT1<\/jats:italic>\n                    ), hepatocyte growth factor (\n                    <jats:italic>HGF<\/jats:italic>\n                    ), angiogenin (\n                    <jats:italic>ANG<\/jats:italic>\n                    ) and transcription factor PROX1. The most downregulated genes in both JEKO-1 and HBL-2 xenografts were midkine (\n                    <jats:italic>MDK<\/jats:italic>\n                    ) and ephrine B2 (\n                    <jats:italic>EPHB2<\/jats:italic>\n                    ). In summary, our results demonstrate an important role of angiogenesis in the biology of MCL and provide preclinical evidence of potent anti-MCL activity of bevacizumab. In addition, gene expression profiling of 94 angiogenesis-related targets revealed several\n                    <jats:italic>in vivo<\/jats:italic>\n                    up-regulated and down-regulated transcripts. The most differentially expressed target in both MCL tumours was\n                    <jats:italic>CD31\/PECAM1<\/jats:italic>\n                    . Whether any of these molecules might represent a potential druggable target in MCL patients remains to be elucidated.\n                  <\/jats:p>","DOI":"10.14712\/fb2013059010026","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:44:49Z","timestamp":1723477489000},"page":"26-31","source":"Crossref","is-referenced-by-count":2,"title":["In Vivo Growth of Mantle Cell Lymphoma Xenografts in Immunodeficient Mice Is Positively Regulated by VEGF and Associated with Significant Up-regulation of CD31\/PECAM1"],"prefix":"10.14712","volume":"59","author":[{"given":"Jan","family":"Molinsk\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kl\u00e1nov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Maswabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ne\u010das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"\u017divn\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Klener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5727","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"fb2013059010026_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.exphem.2010.05.001","volume":"38","author":"Akers","year":"2010","journal-title":"Exp. Hematol."},{"key":"fb2013059010026_2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1074\/mcp.M800515-MCP200","volume":"8","author":"Boyd","year":"2009","journal-title":"Mol. Cell Proteomics"},{"key":"fb2013059010026_3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","volume":"159","author":"Eve","year":"2012","journal-title":"Br. J. Haematol."},{"key":"fb2013059010026_4","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.ejca.2011.02.018","volume":"47","author":"Fang","year":"2011","journal-title":"Eur. J. Cancer."},{"key":"fb2013059010026_5","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood-2005-06-2530","volume":"107","author":"Fragoso","year":"2006","journal-title":"Blood"},{"key":"fb2013059010026_6","doi-asserted-by":"crossref","first-page":"8624","DOI":"10.1158\/0008-5472.CAN-07-0402","volume":"67","author":"Gallay","year":"2007","journal-title":"Cancer Res."},{"key":"fb2013059010026_7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/carcin\/bgi259","volume":"27","author":"Guo","year":"2006","journal-title":"Carcinogenesis"},{"key":"fb2013059010026_8","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"Hess","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"fb2013059010026_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0014-5793(03)00224-2","volume":"540","author":"Jackson","year":"2003","journal-title":"FEBS Lett."},{"key":"fb2013059010026_10","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1158\/1078-0432.CCR-05-0143","volume":"11","author":"Jubb","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"fb2013059010026_11","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"fb2013059010026_12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/205873920601900105","volume":"19","author":"Lazarova","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"fb2013059010026_13","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1158\/1078-0432.CCR-04-2458","volume":"11","author":"Lugli","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"fb2013059010026_14","first-page":"208","volume":"1806","author":"Mahtouk","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"fb2013059010026_15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3324\/haematol.2011.040659","volume":"97","author":"Medina","year":"2012","journal-title":"Haematologica"},{"key":"fb2013059010026_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann. Oncol."},{"key":"fb2013059010026_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"key":"fb2013059010026_18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.2010.08343.x","volume":"151","author":"Poggi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"fb2013059010026_19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/neuonc\/nos130","volume":"14","author":"Sikkema","year":"2012","journal-title":"Neuro Oncol."},{"key":"fb2013059010026_20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2011.09.010","volume":"21","author":"Smedby","year":"2011","journal-title":"Semin. Cancer Biol."},{"key":"fb2013059010026_21","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"fb2013059010026_22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","volume":"50","author":"Stopeck","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"fb2013059010026_23","first-page":"1281","volume":"53","author":"Tsutsui","year":"1993","journal-title":"Cancer Res."},{"key":"fb2013059010026_24","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2004-01-0226","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"fb2013059010026_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1756-8722-3-30","volume":"3","author":"Wang","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"fb2013059010026_26","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann. Oncol."},{"key":"fb2013059010026_27","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1242\/jcs.083998","volume":"124","author":"Yoshimatsu","year":"2011","journal-title":"J. Cell. Sci."},{"key":"fb2013059010026_28","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.96.24.13813","volume":"96","author":"Zou","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Folia Biologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/foliabiologica.lf1.cuni.cz\/media\/pdf\/fb_2013059010026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/foliabiologica.lf1.cuni.cz\/media\/pdf\/fb_2013059010026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:36:10Z","timestamp":1779960970000},"score":1,"resource":{"primary":{"URL":"https:\/\/foliabiologica.lf1.cuni.cz\/59\/1\/0026\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013]]}},"alternative-id":["fb_2013059010026"],"URL":"https:\/\/doi.org\/10.14712\/fb2013059010026","relation":{},"ISSN":["0015-5500","2533-7602"],"issn-type":[{"value":"0015-5500","type":"print"},{"value":"2533-7602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}